There's plenty of support for the notion that a vaccine might not be impossible, might take years and arrive late to the market, or might have a very short duration of effectiveness (aka endurance). Also, it will take years for everyone on the planet to be injected.

Not trying to be argumentative, but on the wild chance that an effective vaccine is available later this year -- what effect do you think it will have on CytoDyn's stock price on a percentage basis?

Do you think the market will have an exaggerated negative knee jerk reaction to anticipated diminished revenue -- or do you think that enough other positive catalysts will have entered the picture by the end of the year to offset the significant erosion of COVID revenue?

Taking it one step further, what if the vaccine becomes available in calendar 2021?

Lastly, in the 6-11-2020 conference call, NP very informally projected revenue of $9B in 2021 based on almost 6M vials that can treat 1.5M patients -- not $11.5B. I realize that Combo HIV (if approved) might provide some revenue contribution in that year -- but I'm not sure you were factoring that in to your $11.5B.